Clinical Trial Update: A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Anitocabtagene Autoleucel versus standard of care in relapsed/refractory multiple myeloma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anitocabtagene Autoleucel (anitocabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING